

Simple, Rapid Antiplatelet Therapy Response Assessment

VerifyNow™



Acute Care Diagnostics

Antiplatelet therapy. Is it working?

- At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological effect^{1,2,3}
- 40% of patients receiving clopidogrel (Plavix®) may not adequately respond to therapy⁴
- Hyper-response is associated with an increased risk of bleeding⁵
- Individual response to antiplatelet therapies can change over time⁶

Thus, understanding a patient's unique response to antiplatelet medications is essential for effective medical decision-making.

VerifyNow testing offers antiplatelet therapy guidance in many clinical scenarios

- Interventional procedures for endovascular aneurysm treatment
- Cardiovascular surgery requiring patients to suspend antiplatelet therapy
- Surgery involving patients taking antiplatelet therapy who are at risk for bleeding

For better patient management

One of the most cited and utilized platelet reactivity testing systems, VerifyNow is an indispensable aid to understanding the complete patient profile. Monitoring patient response to antiplatelet medication optimizes patient outcomes.

VerifyNow testing:

- Offers platelet reactivity results in minutes
- Measures the effect of antiplatelet therapies prior to a procedure or discharge
- Identifies patients at risk for an antiplatelet-related bleeding or thrombotic event
- Identifies therapeutic noncompliance

VerifyNow testing may help:⁷

- Reduce time off antiplatelet therapy and its associated risks
- Reduce the need for standard pre-op platelet orders
- Optimize patient length of stay prior to surgery
- Reduce 30-day readmissions


Variability in antiplatelet response

Factors contributing to variations in patient response to antiplatelet medication include:⁸

- Concomitant medications
- Genetic differences
- Current health conditions
- Patient noncompliance

* PRU = P2Y12 Reaction Units

Decrease in Drug Effect Over Time⁹



Challenge

Patients with inadequate response to antiplatelet medications may be at significantly greater risk of myocardial infarction and stent thrombosis.


A number of commonly prescribed antiplatelet medications block the P2Y12 platelet-receptor, reducing the risk of major adverse cardiac events (MACE).

† Based on patients with Acute Coronary Syndrome not taking a P2Y12 inhibitor

VerifyNow PRUtest™

Measures the level of P2Y12 platelet-receptor blockade to help identify patient response to antiplatelet therapy.

Patient Response to Antiplatelet Therapy^{10†}



Challenge


Whether used alone or as part of a dual antiplatelet therapy, not all patients respond to aspirin equally.

Up to 30% of patients demonstrate lower-than-expected levels of platelet inhibition while on aspirin therapy, putting them at greater risk of heart attack, stroke and other vascular events.^{1,2,3} Alternatively, other patients can exhibit a hyper-response, increasing bleeding risk.²

VerifyNow Aspirin Test

Aids in assessing how aspirin inhibits platelets, allowing rapid, informed treatment decisions.

Patient Response to Aspirin¹¹



Specific drug-receptor site activation


VerifyNow PRUTest

Uses ADP and PGE1 to measure the degree of P2Y12 platelet-receptor blockade, identifying patient response to a P2Y12 inhibitor.

VerifyNow Aspirin Test

Utilizes an arachidonic acid-initiated reaction to measure platelet response to aspirin.

Commonly prescribed antiplatelet medications, including clopidogrel (Plavix®), prasugrel (Effient®) and ticagrelor (Brilinta®/Brilique), block the platelet P2Y12 receptor.



VerifyNow testing supports patient care in many areas of the hospital

- Cardiac Care Unit
- Interventional Neuroradiology Suite
- Emergency Department
- Cardiac Catheterization Laboratory
- Laboratory




Simple integration into any workflow

- Easy to use
- No pipetting or sample preparation
- Sample-to-answer results in a fully contained, single-use test system

Uses Light Transmission Aggregometry (LTA)-correlated technology

- Requires no sample manipulation, eliminating analytical sample variation
- Patented, accurate and intuitive
- Gold standard technology for pharmaceutical drug development



Customer testimonials

“Testing with VerifyNow supports ongoing expansion of the frontiers of endovascular aneurysm treatment by helping minimize risk of perioperative complications.”

Josser E. Delgado, MD

Neurointerventionalist
Abbott Northwestern Hospital
Neuroscience Institute
Minneapolis, Minnesota

“I test all patients on platelet inhibitors prior to open heart surgery to assess whether or not antiplatelet therapies are having their desired effect.”

Pierre R. Tibi, MD

Cardiothoracic Surgeon and Medical Director
The James Family Heart Center at YRMC
West Prescott, Arizona

“Having the VerifyNow system allows me to assess the effect of the chosen antiplatelet treatment strategies and make informed decisions.”

J. Brent Muhlestein, MD

Interventional Cardiologist
Intermountain Heart Institute
Murray, Utah

References

- Gurbel PA, et al. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol.* 2007;50(19):1822–34.
- Krasopoulos G, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. *BMJ.* 2008;336(7637):195–8.
- Steinhubl SR, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU - Assessing Ultegra) multicenter study. *Circulation.* 2001;103(21):2572–8.
- Stone G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet.* 2013;382(9892):614–23.
- Aradi D, et al. Bleeding and Stent Thrombosis on P2Y12-inhibitors: Collaborative Analysis on the Role of Platelet Reactivity for Risk Stratification after Percutaneous Coronary Intervention. *European Heart Journal.* 2015;36(27):1762–71.
- Delgado Almandoz JE, et al. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. *Journal of NeuroInterventional Surgery.* 2014;6:767–73.
- Brizzio ME, et al. Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage. *J Invasive Cardiol.* 2012;24(2):49–52.
- Serebruany, VL, et al. Variability in Platelet Responsiveness to Clopidogrel among 544 Individuals. *Journal of the American College of Cardiology*, vol. 45, no. 2, 2005, pp. 246–251.
- Price MJ, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. *J Am Coll Cardiol.* 2012;59(25):2338–43.
- VerifyNow PRUTest [package insert]. San Diego, CA; Accriva Diagnostics.
- VerifyNow Aspirin Test [package insert]. San Diego, CA; Accriva Diagnostics.

Werfen

Corporate Headquarters

Plaza de Europa, 21–23
08908 L'Hospitalet de Llobregat
Barcelona, Spain
+34-93-4010101
werfen.com

Instrumentation

Laboratory Headquarters

180 Hartwell Road
Bedford, MA 01730 USA
+1-781-861-0710
instrumentationlaboratory.com

Worldwide Locations

The Americas

Brazil
São Paulo
+55-11-46227878
br.werfen.com

Canada
Richmond Hill, ON
+1-800-552-2025 x6115
instrumentationlaboratory.com

Colombia
Bogotá
+57 15 221 052

Mexico
Mexico City
+52-55-5262-1760
mx.werfen.com

Uruguay
Montevideo
+5982-481-81-33

USA
Bedford, MA
+1-781-861-0710
instrumentationlaboratory.com

Asia-Pacific

Australia
Sydney
+61-02-9098-0200
au.werfen.com

China
Beijing
+86-10-59756055
Hong Kong
+852-2792-7773
Shanghai
+86-21-66308671
cn.werfen.com

India
New Delhi
+91-490-29-550
in.ilwerfen.com

Japan
Tokyo
+81-3-5419-1301
jp.werfen.com

Korea
Seoul
+82-1899-9217
kr.werfen.com

Thailand
Bangkok
+66-271-226-28/9

Europe

Austria
Vienna
+43-1-256-58-000
at.werfen.com

Belgium
Brussels
+32-2-7252052
benelux.werfen.com

Czech Republic
Prague
+420-246-090-931
cz.werfen.com

France
Paris
+33-182-30-86-00
fr.werfen.com

Germany
Munich
+49-89-909070
de.werfen.com

Hungary
Budapest
+36-1-882-73-10
hu.werfen.com

Italy

Milan
+39-02-25221
it.werfen.com

Lithuania
Kaunas
+370-37-313157
lt.werfen.com

The Netherlands
Breda
+31-76-5480100
benelux.werfen.com

Poland
Warsaw
+48-22-336-18-00

Portugal
Lisbon
+351-214247312
pt.werfen.com

Russia
Moscow
+7-499-124-45-59
ru.ilwerfen.com

Spain

Barcelona
+34-902-20-30-90
es.werfen.com

UK
Warrington, England
+44-1925-810141
uk.werfen.com

For all other countries visit
international.werfen.com